No Data
Galectin Therapeutics Highlights Promising NAVIGATE Trial Results
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
Galectin Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Galectin Therapeutics Analyst Ratings
H.C. Wainwright Downgrades Galectin Therapeutics(GALT.US) to Hold Rating
H.C. Wainwright Downgrades Galectin Therapeutics After MASH Trial Fails